share_log

Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target

Moomoo 24/7 ·  Apr 16 07:41

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $25 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment